Reported 4 months ago
The article discusses the growth and potential risks for Eli Lilly and Novo Nordisk, two valuable healthcare companies with GLP-1 drugs in their portfolios. Despite their significant rise in stock value over the past five years, investors should be wary of potential competition in the GLP-1 weight loss market as more companies develop similar drugs. The article highlights the importance of closely monitoring upcoming rival treatments, such as MariTide from Amgen, which could challenge the dominance of Eli Lilly and Novo Nordisk in the future.
Source: YAHOO